1. Home
  2. CUE vs EHGO Comparison

CUE vs EHGO Comparison

Compare CUE & EHGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • EHGO
  • Stock Information
  • Founded
  • CUE 2014
  • EHGO 2015
  • Country
  • CUE United States
  • EHGO China
  • Employees
  • CUE N/A
  • EHGO N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • EHGO
  • Sector
  • CUE Health Care
  • EHGO
  • Exchange
  • CUE Nasdaq
  • EHGO NYSE
  • Market Cap
  • CUE 94.4M
  • EHGO 90.4M
  • IPO Year
  • CUE 2018
  • EHGO 2024
  • Fundamental
  • Price
  • CUE $1.38
  • EHGO $1.12
  • Analyst Decision
  • CUE Strong Buy
  • EHGO
  • Analyst Count
  • CUE 5
  • EHGO 0
  • Target Price
  • CUE $5.00
  • EHGO N/A
  • AVG Volume (30 Days)
  • CUE 245.9K
  • EHGO 71.7K
  • Earning Date
  • CUE 03-10-2025
  • EHGO 02-28-2025
  • Dividend Yield
  • CUE N/A
  • EHGO N/A
  • EPS Growth
  • CUE N/A
  • EHGO N/A
  • EPS
  • CUE N/A
  • EHGO 0.00
  • Revenue
  • CUE $9,532,000.00
  • EHGO $16,963,957.00
  • Revenue This Year
  • CUE $73.11
  • EHGO N/A
  • Revenue Next Year
  • CUE $11.02
  • EHGO N/A
  • P/E Ratio
  • CUE N/A
  • EHGO $2,944.55
  • Revenue Growth
  • CUE 149.53
  • EHGO N/A
  • 52 Week Low
  • CUE $0.45
  • EHGO $0.91
  • 52 Week High
  • CUE $2.37
  • EHGO $5.50
  • Technical
  • Relative Strength Index (RSI)
  • CUE 52.01
  • EHGO N/A
  • Support Level
  • CUE $1.22
  • EHGO N/A
  • Resistance Level
  • CUE $1.50
  • EHGO N/A
  • Average True Range (ATR)
  • CUE 0.12
  • EHGO 0.00
  • MACD
  • CUE -0.00
  • EHGO 0.00
  • Stochastic Oscillator
  • CUE 55.38
  • EHGO 0.00

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

About EHGO ESHALLGO INC

Eshallgo Inc. focuses on two distinct market sectors: office supply sale and leasing, and after-sale maintenance and repair. It is an authorized distributor of brands of office equipment, including HP, Epson, Xerox, Sharp, Toshiba, Konica, Kyocera, and other brands.

Share on Social Networks: